1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shanghai Kaibao Pharmaceutical CO.,Ltd

Shanghai Kaibao Pharmaceutical CO.,Ltd

300039.SZ
Shanghai Kaibao Pharmaceutical CO.,LtdCN flagShenzhen Stock Exchange
4.41
CNY
+0.03
- -
4.61BMarket Cap
Shanghai Kaibao Pharmaceutical CO.,Ltd
300039.SZ
(Shenzhen Stock Exchange)

Recent

price

4.41

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.57
0.77
1.03
1.24
1.52
1.29
1.4
1.46
1.42
1.36
0.87
1.05
1.07
1.52
1.41
1.1
1.19
Revenue per Share
0.12
0.16
0.23
0.3
0.33
0.26
0.26
0.25
0.21
0.24
0.1
0.13
0.18
0.31
0.36
0.27
0.34
Basic EPS, GAAP
-0.03
0.03
0.18
0.14
0.19
0.26
0.27
0.18
0.22
0.3
0.23
0.08
0.33
0.34
0.13
0.19
-0.02
Free Cash Flow per Basic Share
0.03
0.07
0.15
0.12
0.13
0.12
0.08
0.1
0.1
0.1
0.1
0.03
0.05
0.06
0.1
0.13
0.1
Dividend per Share
0.3
0.46
0.51
0.9
1.22
1.5
1.67
2
2.12
2.24
2.23
2.32
2.5
2.72
2.95
3.13
2.96
Book Value per Share
1.13
1.23
1.3
1.46
1.72
1.81
2.01
2.17
2.32
2.42
2.41
2.86
3.54
3.81
3.76
4.07
3.92
Tangible Book Value per Share
1,068
1,062
1,068
1,068
1,068
1,082
1,073
1,072
1,059
1,046
1,046
1,046
1,046
1,046
1,046
1,046
1,046
Basic Weighted Avg Shares
603
820
1,102
1,323
1,621
1,396
1,497
1,570
1,501
1,419
908
1,101
1,119
1,594
1,473
1,153
1,249
Sales/Revenue/Turnover
19.42
19.93
22.12
25.18
24.49
21.63
21.07
19.97
20.37
19.97
10.44
12.1
18.27
20.7
25.04
23.64
27.19
Operating Margin (%)
13
22
27
30
44
51
51
49
48
48
41
34
32
38
36
35
- -
Depreciation Expense
124
168
242
319
352
282
283
272
227
251
106
140
191
328
376
279
355
Net Income, GAAP
16.02
15.46
15.37
15.46
15.69
15.88
15.19
16.84
17.43
16.67
19.36
17.41
15.96
14.77
13.65
13.68
13.4
Effective Tax Rate (%)
20.5
20.44
21.98
24.09
21.71
20.18
18.88
17.35
15.11
17.69
11.69
12.73
17.05
20.57
25.49
24.17
28.46
Profit Margin (%)
1,034
1,096
1,188
1,270
1,469
1,542
1,636
1,822
1,935
2,024
1,982
2,064
1,278
1,140
2,183
2,071
2,352
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1,237
1,334
1,419
1,606
1,887
2,006
2,200
2,365
2,496
2,569
2,578
3,045
3,761
4,033
4,103
4,419
4,264
Total Equity
7.83
10.69
14.91
18.54
18.85
12.86
12.75
11.46
10.39
9.31
2.95
3.9
5.04
7.17
7.77
5.47
7.55
Return on Invested Capital (%)
40.53
41.57
43.03
39.34
29.1
19.18
16.55
13.86
10.34
10.94
4.52
5.84
7.59
12.05
12.69
8.78
11.9
Return on Capital (%)
50.15
41.57
46.81
42.13
31.03
19.25
16.55
13.85
10.34
10.94
4.54
5.88
7.56
12.02
12.68
8.77
11.89
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
5
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,046
1,046
1,046
Market Capitalization
6,462
6,610
6,338

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,415
2,711
2,555
Cash, Cash Equivalents & STI
773
879
800
Accounts Receivable, Net
317
321
234
Inventories
188
186
203
Total Current Liabilities
232
285
202
Payables & Accruals
- -
- -
- -
ST Debt
5
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.43%
11.66%
7.69%
Free Cash Flow
23.86%
47.39%
47.16%
Net Income, GAAP
6.17%
25.75%
-25.83%
Sales/Revenue/Turnover
0.23%
7.2%
-21.76%
Total Cash Common Dividend
- -
22.42%
30%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
475
354
292
352
1,473
2025
401
204
334
- -
1,153
2026
283
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
- -
- -
- -
0.36
2025
0.08
- -
- -
- -
0.27
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.1
2025
- -
- -
- -
- -
0.13
2026
- -
- -
- -
- -
- -
Similar Companies
Luff Enterprises Ltd. (LUFF.CN)
Genix Pharmaceuticals Corporation (GENPF)
JW Pharmaceutical Corporation (001060.KS)
Takeda Pharmaceutical Company Limited (4502.T)
North American Cannabis Holdings, Inc. (USMJ)
Syncom Formulations (India) Limited (SYNCOMF.BO)
Business
Shanghai Kaibao Pharmaceutical Co., Ltd. (300039.SZ) is a China-based pharmaceutical company principally engaged in the research, development, production, and sales of modern traditional Chinese medicines. The company offers a portfolio of products including Tanreqing injection and Tanreqing capsules for the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infections; tiopronin for injection and tiopronin enteric-coated tablets for improving liver function and adjuvant treatment of various acute and chronic hepatitis; Xiongdan dropping pills to clear heat, calm the liver, and improve eyesight; as well as phlegm heat removal injection and other formulations such as solid dosage forms, oral liquids, small volume injections, tablets, hard capsules, and granules targeting respiratory, cardiovascular and cerebrovascular, and digestive diseases. Founded in 2000 and headquartered at No. 88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, China, the company operates primarily in China through subsidiaries including Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd., Shanghai Kaibao Equity Investment Management Co., Ltd., and Shanghai Kaibao Health Technology Co., Ltd. In recent developments, its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical received approval for Doxofylline tablets, a treatment for bronchial asthma, wheezing chronic bronchitis, and bronchospasm-related respiratory difficulties that has passed consistency evaluation; the company also obtained clinical trial approval for KBZ24020 and continues to advance its three core product lines in respiratory, cardiovascular, and digestive domains.